Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new pill take on Hard-to-Treat leukemia?

NCT ID NCT07719348

Not yet recruiting Disease control Sponsor: Servier Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This early-phase trial is testing an experimental drug called S241656, taken as a tablet, in people with relapsed or refractory acute myeloid leukemia (AML) and related blood cancers. The study aims to find a safe dose and see how the drug behaves in the body, both alone and when combined with another medication. Participants will receive the drug in 28-day cycles and be closely monitored for side effects and disease response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called S241656, taken as tablets by mouth, sometimes combined with another drug (posaconazole)
What this could lead to
If this trial succeeds, it could point toward a new treatment option for people with hard-to-treat myeloid blood cancers.
What could go wrong
This is an early-phase trial with only 64 participants, so the drug may not prove safe or effective enough to move forward. Side effects are unknown and will be closely monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia chronic myelomonocytic leukemia GATA2 Deficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA CHRONIC MYELOMONOCYTIC LEUKEMIA MYELODYSPLASTIC SYNDROME ACUTE MYELOID LEUKEMIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.